Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study
Sign Up to like & getrecommendations! Published in 2018 at "Oncology"
DOI: 10.1159/000486788
Abstract: Background: Radioimmunotherapy (RIT) is effective in treating relapsed/refractory follicular lymphoma (FL), with durable remissions in first-line consolidation. We hypothesized that RIT with ibritumomab tiuxetan (Zevalin®) would result in durable remissions by eliminating minimal residual disease… read more here.
Keywords: zevalin; tiuxetan zevalin; disease; ibritumomab tiuxetan ... See more keywords